Although anti-fungal triazoles are dosed orally or systemically for Aspergillus fumigatus infection, systemic adverse events and limited exposure of the lung cavity would make a topical treatment for the lung an attractive option. In this study, we examined the effects of intranasally dosed posaconazole on survival rates and biomarkers in 
| INTRODUCTION
Posaconazole is a second-generation triazole anti-fungal agent with a broad spectrum, and has been approved for treatment of pulmonary aspergillosis. 1, 2 However, oral treatment of posaconazole occasionally shows systemic side effects including diarrhoea, nausea, QTc prolongation and rarely torsade de pointes. 3, 4 In addition, Aspergillus colonisation following infection can occur in preexisting lung cavities caused by tuberculosis or sarcoidosis or on airway surfaces where the fungus firstly deposits and grows, and it is difficult to deliver and maintain appropriate levels of the treated drug after oral treatment at these sites. 1, 2, 5 Thus, there are several advantages of topical treatment over oral/systemic treatment which favourably alter the risk-benefit ratio of treatment.
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Amphotericin B, a polyene anti-fungal agent, is the only anti-fungal agent dosed via the inhaled route. 6, 7 The agent has poor oral absorption and its use as an intravenous infusion is complicated by an adverse effect on the kidney. 8 Inhaled amphotericin B is effective in treatment for pulmonary aspergillosis without the risk of systemic toxicities. 6, 7 Voriconazole, a triazole with potent anti-fungal activity against
Aspergillus species, is available as oral administration or intravenous infusion. Recently voriconazole was also dosed via the pulmonary route, and showed good efficacy, 9 avoiding drug-drug interactions 10 and systemic side effects 11 . The main drawbacks of inhaled amphotericin B and voriconazole include poor adherence to treatment because frequent administration is required.
Itraconazole is another azole used to treat Aspergillus infection.
McConville et al. 12 demonstrated that a single dose of nebulised itraconazole maintained high concentrations in lung in mice for more than 24 hours and it has also been demonstrated in rats. 13 Furthermore the survival rates of the group of mice receiving nebulised itraconazole were significantly higher than the group of mice receiving oral itraconazole administration. 14 Posaconazole, the most potent triazole, has longer tissue retention than itraconazole or voriconazole, [15] [16] [17] but topical treatment of posaconazole, as a potential option for the treatment, has not been tested in vivo.
In this study, therefore, we examined the effects of intranasally dosed posaconazole on biomarkers and survival rates vs both itraconazole-susceptible (ATCC13073: Af) and -resistant (NCPF7100:
AfR) Aspergillus fumigatus-infected immunocompromised mice, and in comparison with those obtained after oral treatment.
| MATERIALS AND METHODS

| Materials
The materials used were obtained from the following sources: Tetracycline 
| Animals
Specific pathogen-free A/J mice (male, 5 weeks old) were purchased from Sankyo Labo Service Co. Ltd. (Tokyo, Japan) and adapted for 1 week in a temperature (24 ± 1°C) and humidity (55% ± 5%) controlled room with a 12 hours day-night cycle. The mice were reared on a standard diet and tap water ad libitum.
| Aspergillus fumigatus strains
The itraconazole-susceptible strain, ATCC13073 (Af; NIH 5233 strain), and itraconazole-resistant strain, NCPF7100 (AfR; AF90, M220V mutation), were purchased from American Type Culture Collection (Manassas, VA, USA) and Culture Collections, Public Health England (Salisbury, UK), respectively. 
| MIC determinations
| Survival study
Animal body weights were monitored daily and if it fell by >20% compared to that on day 1 (when posaconazole treatment started), animals were defined as dropout and were sacrificed using a high dose of pentobarbital. Posaconazole was administered either intranasally (35 μL of a suspension in physiological saline, approximately 17.5 μL into each nostril) under anaesthesia with 3% isoflurane or orally (5 mL/kg of a suspension in PEG400 in physiological saline) once daily for 7 days from 30 minutes before infection or from a day after conidia inoculation. Particularly, the volume used for intranasal treatment (35 μL) is reported to achieve 60% deposition of lung. 
| Galactomannan determination
Galactomannan (GM) in BALF and serum was determination using
Platelia Aspergillus-EIA kits (Bio-Rad Laboratories, Redmond, WA, USA). BALF and serum samples were mixed with sample treatment solution provided in the kit, then centrifuged and the both supernatants were diluted 20-or 10-fold with PBS, respectively. Cut-off index (COI) was calculated by the formula: Cut-off index=(OD in sample)/ (OD in cut-off control provided as part of the kit). 
| Aspergillus fumigatus load determination (CFU)
One
| Whole lung histological analysis
Whole lungs were fully inflated by intratracheal perfusion with 10%
formalin neutral buffer solution. Routine histological techniques were used to prepare paraffin-embed tissue, and 4-μm sections of whole lung were stained with haematoxylin and eosin, and Grocott's methenamine silver (GMS) stain kit (Silver Stain Kit, Sigma HT100A). 
| Aspergillus fumigatus DNA analysis
| Statistical analysis
Results are expressed as means±standard error of the mean (SEM).
Survival analysis was performed by Kaplan-Meier plots followed by the log rank (Mantel-Cox) tests. Statistical significance was defined as P < .05.
| RESULTS
| MICs for ATCC13073 (Af) and NCPF7100 (AfR)
Af strain was highly susceptible to posaconazole, which was eightfold more potent than voriconazole. In contrast, AfR strain was 17 times less susceptible to posaconazole, and >64-fold less susceptible to itraconazole, although voriconazole showed similar MIC values in both strains tested. Thus, AfR was resistant to posaconazole and itraconazole as previously reported (Table 1) . We did not observe any adverse events associated with intranasal treatment of posaconazole in this dosing regimen. As well as the level of GM and CFU, inflammatory and other markers were elevated after Aspergillus infection. As seen in Figure 2E and F, alveolar macrophages and neutrophils in BALF were slightly increased by A. fumigatus infection. An oxidative stress marker, MDA (TBARS reactive molecule), showed induction just after infection, and then gradually increased between days 3 and 6 in BALF ( Figure 2G ).
| Kinetics of biomarkers in
IFN-γ and IL-17 in BALF seemed to increase in a time-dependent manner up to day 8 ( Figure 2H and I).
| Effects of intranasal posaconazole on fungal load and fungal biomarkers in Aspergillus fumigatus (Af) infected mice
Early intervention by intranasal posaconazole produced potent, dose-dependent inhibition of GM in BALF and serum ( Figure 3A , and mice were sacrificed 6 hours after the last dose of drug, and then bronchoalveolar lavage fluid (BALF), serum and lungs were collected for Galactomannan (GM) and CFU analysis. Each value is presented as mean±SEM (n = 6). Significant difference from vehicle control value at *P < .05 or **P < .01 or ***P < .001 
| Effects of intranasal posaconazole on infectionassociated biomarkers in Aspergillus fumigatus (Af)-infected mice
Accumulation of macrophage and neutrophils and the levels of other markers such as MDA, IFN-γ and IL-17 in BALF were significantly reduced by early intervention of intranasal posaconazole and the effects were more potent than the late intervention ( Figure S3A and B, Table 2 ). The value is compared with vehicle control. The complete inhibition by intranasal posaconazole was also confirmed by histology where fungus was visualised by silver staining (Figure 4) . Thus, greater maximum inhibition was obtained by intranasal than oral treatment over the doses ranges studied here, but assessed by calculated ID 50 values, intranasal treatment was less potent vs those fungal biomarkers than oral treatment.
| DISCUSSION
In our temporarily neutropenic model, marked production of IL-17 and IFN-γ was observed in BALF after A. fumigatus infection ( Aspergillus fumigatus infection was reported to incrementally increase MDA levels caused by the oxidant-antioxidant imbalance in neutropenic mice lung homogenates. 31 We also found that MDA was increased during A. fumigatus infection. MDA was highly induced just after infection probably as a part of host defence, and then gradually increased overtime, peaking between days 4 and 6, when fungal biomarkers also peaked ( Figure 2G ). As MDA kinetics resembled fungal biomarkers, the change in oxidative stress was apparently associated with A. fumigatus growth, suggesting that MDA will be an interesting marker of A. fumigatus infection. The elevated MDA levels also responded well to intervention with intranasal posaconazole.
The lack of pharmacokinetic measurement of posaconazole concentrations in plasma and ELF is a limitation of this study. It is therefore difficult to interpret the different effects of two administration routes, although we found that both oral and intranasal treatment improved survival proportions similarly. However, we carefully optimised the intranasal volume (35 μL), and as previously reported, 19 35 μL of intranasal volume is expected for 60% of inoculum to deposit in lung. This means 40% of inoculum or treated posaconazole might be swallowed or stayed in nasal cavity, and therefore it cannot be ruled out that intranasally treated posaconazole was exposed systemically via gastrointestinal route or nasal route. Seyedmousavi et al., 20 who evaluated the pharmacokinetic parameters of posaconazole in immunosuppressed mice, suggested that high plasma protein binding may explain the reason why effective local concentrations can be achieved, even at the low dose. In addition, it has been suggested that the more hydrophobic posaconazole allows an even higher intracellular uptake than voriconazole. 32 This would suggest that posaconazole would be the better candidate for topical treatment than voriconazole. However, we report here that oral posaconazole was more potent than intranasal posaconazole on biomarkers based on the ID 50 values, and so are unlikely to be ideal for topical treatment.
We demonstrated that intranasally dosed posaconazole produced potent inhibition of A. fumigatus-induced inflammation, fungal load and improvement of survival rate. These findings suggest that topical administration of posaconazole is a potential option for the treatment of A. fumigatus infection in humans with higher efficacy and less toxicities.
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